While immune checkpoint inhibitors have revolutionized oncology, still only 20-30% of patients respond to PD-1/PD-L1 antibody monotherapy. This can be due to a failure of T cells to recognize “cold” tumors (low T-cell infiltrates).
Increasing evidence exists regarding estrogen receptor β (ERβ) playing a protective role in Alzheimer’s disease (AD) and its loss resulting in progressive neural cell body degeneration.
